Building conviction is hard. See your asset the way partners will.
Prudentia closes the information gap between buyers and sellers before diligence begins.
Schedule demoSchedule demo
What you don’t know about your asset can hurt you
Most biotech teams have done only a handful of deals. Buyers and investors have seen thousands. Prudentia helps you identify blind spots early and shape how your asset is evaluated long before engagement.
“How did we miss that risk in internal data review?”
“We saw the risk early and addressed it before it became an issue.”
“Our asset is worth more than they’re offering.”
“Here’s why it’s worth more, and here’s the data to back it up.”
“Why is it so hard to get to the deal-table with Pharma?”
“We walked in speaking the BD team’s language, with a defensible narrative that held up.”
“How did we miss that risk in internal data review?”
“Our asset is worth more than they’re offering.”
“Why is it so hard to get to the deal-table with Pharma?”
“We saw the risk early and addressed it before it became an issue.”
“Here’s why it’s worth more, and here’s the data to back it up.”
“We walked in speaking the BD team’s language, with a defensible narrative that held up.”
Prudentia in practice
Identifying unseen risk before investor conversations
A CNS biotech preparing for its first institutional raise used Prudentia to assess its lead asset. By combining internal data with external evidence, the team uncovered critical regulatory strategy and preclinical safety risks, in addition to suboptimal portfolio prioritization strategy. Early identification of these risks allowed them to revisit their strategy and refine how the asset would be presented before engaging investors.
Identified previously unknown scientific risk
Reprioritized lead program, indication, and development strategy
Strengthened investor positioning across the full portfolio
Maintaining a clear view of a fast-moving competitive landscape
A clinical-stage immunology biotech used Prudentia to assess its asset and monitor a rapidly evolving global competitive landscape, including emerging companies in the space. Instead of relying on fragmented sources and manual tracking, the team built a continuously updated view of competitor activity and benchmarked their asset across both in-market and emerging programs.
Built a unified, global view of competitor activity
Benchmarked asset against peers with consistent criteria
Strengthened positioning in external partner discussions
Evaluate, benchmark, and position your asset in one place
Apply the same lens used in diligence to understand your asset, its value, and how it will be seen by investors and partners.
Build a complete view of your asset
Leave no stone unturned with rigorous scientific assessment
Position your asset with confidence
Our Partners
Leading investors supporting the future of life sciences
AI that accelerates your judgment in deal-making
Prudentia brings together data, expert frameworks, and AI to produce outputs grounded in evidence and ready for decision-making.
Scientific diligence frameworks
Apply expert-developed frameworks to evaluate assets consistently
Assess biological mechanism validity and plausibilityEvaluate translational, regulatory, and clinical riskModel pTRS, NPV, and development scenariosAI reasoning, grounded in evidence
Scale scientific reasoning across deals
Models trained for therapeutic area and modalities, across drug development life cycleAI agents that understand drug development risks and opportunitiesEnd-to-end data provenance, with human-in-the-loop validationCentralized evidence
Unify fragmented data sources into a single, connected evidence base
Securely connect to all necessary data sourcesIntegrate public, proprietary, and internal datasetsOrganize all evidence within your company-specific systemProtected by design
Life sciences dealmaking involves some of the most sensitive data in the industry.
Visit our Trust CenterVisit our Trust Center
Secure Private Infrastructure
Single-tenant deployment with your data siloed and never shared across customers
Granular access controls
SSO integration with granular access controls and permissions
Data protected end-to-end
Encryption at rest and in transit, with complete audit trails
Built-in compliance
Your data is never used to train models, aligned with ISO/IEC 42001:2023